ARTELO BIOSCIENCES, INC. (OTCMKTS:ARTL) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD. Disclosure.
On May 11, 2017, representatives of Artelo Biosciences, Inc. (the
Company) began making presentations to potential
investors using slides containing the information attached as
Exhibit 99.1 to this Current Report on Form 8-K
(the Investor Presentation) and incorporated by
reference herein. The Company expects to use the Investor
Presentation, in whole or in part, and possibly with
modifications, in connection with presentations to potential
investors and others at talks to be held on May 11 and May 12 in
London and Dublin, respectively.
By filing this Current Report on Form 8-K and furnishing the
information contained herein, the Company makes no admission as
to the materiality of any information in this report that is
required to be disclosed solely by reason of Regulation FD.
The information furnished to Item 7.01 of this Current Report on
Form 8-K (including the exhibit) does not constitute an offer to
sell or a solicitation of an offer to purchase any securities of
the Company and does not constitute an offer, solicitation or
sale in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful.
The information presented in Item 7.01 of this Current Report on
Form 8-K and Exhibit 99.1 shall not be deemed to
be filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act), or
otherwise subject to the liabilities of that section, unless the
Company specifically states that the information is to be
considered filed under the Exchange Act or specifically
incorporates it by reference into a filing under the Securities
Act of 1933, as amended, or the Exchange Act.
This Current Report on Form 8-K contains forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements are not
guarantees of future performance. These forward-looking
statements reflect views and assumptions regarding expectations
and projections about future events and are based on currently
available information. The use of words such as anticipates,
estimates, expects, intends, plans, and believes, among others,
generally identifies forward-looking statements. However, these
words are not the exclusive means of identifying such statements.
In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances are forward-looking statements and may include
statements relating to future revenues, expenses, margins,
profitability, net income/(loss), earnings per share and other
measures of results of operations and the prospects for future
growth of the Companys business. These forward-looking statements
are inherently subject to uncertainties, risks and changes in
circumstances that are difficult to predict.
Actual results and the timing and outcome of events may differ
materially from those expressed or implied in these
forward-looking statements for a variety of reasons, including,
but not limited to: an increasingly competitive global
environment; risks related to the Companys industry; the results
of the Companys sponsored research; the Companys failure to
comply with current laws, rules and regulations, or changes to
such laws, rules and regulations; volatility in the Companys
stock price; liquidity constraints or the Companys inability to
access the capital markets when necessary or desirable; risks
related to actions taken by the Companys business partners and
third party service providers; the Companys failure to protect
its intellectual property or proprietary information from copying
or use by others; and other risks detailed in the Companys public
filings with the SEC.
Other unknown or unpredictable factors also could have a material
adverse effect on the Companys business, financial condition and
results of operations. In addition, in light of these risks and
uncertainties, the matters referred to in the forward-looking
statements contained in this Current Report on Form 8-K may not
in fact occur. Accordingly, the reader should not place undue
reliance on those statements. Except as required by law, the
Company undertakes no obligation, and does not intend, to
publicly or otherwise update or revise any forward-looking
statement or other statement in this Current Report on Form 8-K,
whether as a result of new information, future events or
otherwise, even if experience or future events make it clear that
any expected results express or implied by these forward-looking
statements will not be realized.
Item 9.01 Financial Statements and Exhibits.
About ARTELO BIOSCIENCES, INC. (OTCMKTS:ARTL)
Artelo Biosciences, Inc., formerly Reactive Medical Inc., is focused on becoming a specialty biopharmaceutical company. The Company intends to license, develop and commercialize novel cannabinoid therapeutic treatments for unmet medical needs. It intends to develop its own drugs and delivery methods by conducting clinical efforts through existing and new contracted research collaborations. As of April 14, 2017, the Company had not generated any revenue.